IRL752 fumarate displays its highest in vitro affinities for 5-HT and NA-related targets [2].

IRL752 (3.7-100 μmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function [2]. Animal Model: Normal rats [2] Dosage: 3.7-100 μmol/kg Administration: S.c., 30 min prior to testing Result: Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.